NODAL PERIPHERAL T-CELL LYMPHOMA WITH TFH PHENOTYPE
Clinical trials for NODAL PERIPHERAL T-CELL LYMPHOMA WITH TFH PHENOTYPE explained in plain language.
Never miss a new study
Get alerted when new NODAL PERIPHERAL T-CELL LYMPHOMA WITH TFH PHENOTYPE trials appear
Sign up with your email to follow new studies for NODAL PERIPHERAL T-CELL LYMPHOMA WITH TFH PHENOTYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise in Hard-to-Treat blood cancer
Disease control Recruiting nowThis phase 3 trial tests a new oral drug, soquelitinib, against standard single-agent chemotherapy in 150 adults with relapsed or refractory peripheral T-cell lymphoma. The study aims to see if soquelitinib can delay cancer progression better than current options. Participants ar…
Matched conditions: NODAL PERIPHERAL T-CELL LYMPHOMA WITH TFH PHENOTYPE
Phase: PHASE3 • Sponsor: Corvus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Massive T-Cell lymphoma database aims to unlock new insights
Knowledge-focused Recruiting nowThis study is creating a large database of information and tissue samples from 1,000 people with T-cell lymphoma. Researchers will use this data to learn more about the disease and how to improve patient outcomes. Participants provide medical information and optional blood and na…
Matched conditions: NODAL PERIPHERAL T-CELL LYMPHOMA WITH TFH PHENOTYPE
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC